How to build a defensible specialty-crop market assessment when the data is incomplete

In the previous article, I argued that agricultural market intelligence is still detective work. This article takes the next step: turning that detective work into a defensible specialty-crop market assessment.

In specialty crops, the market opportunity is rarely completely unknown. More often than not, it is misunderstood, overstated, understated, or misclassified. Companies may point to total crop production value and call it their market. Teams may start with planted acres and assume every acre is equally addressable. Early-stage companies may assume that a biological, botanical, or biorational story will naturally expand as organic acreage increases. The opposite mistake also occurs: companies conclude that a market is too small because the available dataset fails to capture the category they are trying to measure.

A good market assessment does not make uncertainty disappear. It makes uncertainty manageable. That is the purpose of sizing the unseen: not to force false precision into an uncertain market, but to separate what is known from what is assumed and build a decision-ready view of where the real commercial opportunity may exist.

Specialty-crop economics are complex and uneven. Labor, harvest, packaging, food safety, fertility, water, energy, compliance, crop protection, equipment, and custom services all compete for the same dollars. Depending on the crop and production system, plant protection may be a meaningful spend category, but it is still only one layer within a larger economic picture. That is why the spend stack matters.

For a crop protection product, the total crop value is not the market. Total production cost is not the market. Even total plant protection spend may overstate the opportunity if the product only fits a specific pest complex, timing window, crop stage, production system, or program function. The assessment has to move from broad economics to the relevant, addressable opportunity.

Once the spend stack is explicit, the discussion becomes more useful. Instead of arguing over a single large number, the team can discuss the assumptions that actually matter: crop fit, application frequency, category share, adoption wedge, channel pathway, and evidence quality.

Innovators naturally want to talk about what the market could become. That is understandable. New products often aim to change behavior, create a category, replace a less desirable input, or open a new use pattern. Commercial decision-makers usually need to start with a different question: what exists today, and how does that market actually operate?

Those are different lanes. The first is the current market. It is observable, narrower, and more defensible. It may include current product use, known program behavior, visible crop protection spend, reported applications, channel feedback, and direct input from growers or advisors.

The second lane is modeled potential, the market that could emerge if behavior, programs, or adoption patterns change. It is broader and often more attractive, but it depends on assumptions. It may include market creation, conversion from existing products, replacement of current practices, expanded program usage, or adoption in crops where the product does not yet have a meaningful footprint.

Both views are useful. The problem comes when they are blended. When existing reality and modeled upside are combined into a single number, the story may get bigger, but the decision gets weaker. When the two views are separated, leadership can see what is real now, what must change, and where the company is making a strategic bet.

 Biologicals and biorationals are often difficult to track in market data. Some products are clearly visible in public or commercial datasets. Others are inconsistently reported, exempt, aggregated into broader categories, private-labeled, or blended into adjacent product functions. Ingredient-level attribution can be unclear, particularly when adjuvants, co-formulants, tank-mix partners, and enablement products sit at the edge of what available data can reliably capture. This is where market assessments often lose credibility.

The mistake is to hide the gap, overstate confidence, or present the model as more precise than the evidence allows. A stronger approach is to label the evidence clearly. The assessment should distinguish what can be observed directly, what can be inferred from related data, what must be estimated through assumptions, and which assumptions have the greatest influence on the answer. It should also identify what still needs validation through grower interviews, PCA input, channel checks, expert review, or field-level use data.

This does not weaken the assessment. It strengthens it. Executives do not need false precision. They need to understand the opportunity, the confidence level behind it, and the assumptions that could change the commercial decision.

Several sizing traps appear once an assessment moves beyond broad acreage and estimated dollars. Controlled environment agriculture is one of the most common. Protected production should not be treated as open-field agriculture under glass. Square footage, crop turns, facility utilization, production intensity, and acre-equivalent assumptions need to be explicit. Program intensity also matters. Rotation speed, labor access, re-entry expectations, odor or residue tolerance, phytotoxicity risk, beneficial-insect programs, and compatibility with existing IPM practices can all affect realistic use. A product may work agronomically and still face operating constraints that limit its commercial role.

Organic production creates a different but related risk. It is tempting to assume that organic growth will naturally pull biologicals or biorationals forward. Sometimes it does. But organic production is rarely the whole adoption story, and in many markets it is not the strongest adoption wedge. Stronger adoption wedges may include resistance management, residue constraints, export MRL risk, worker safety, re-entry timing, compatibility with beneficials, retailer standards, or the need for a softer tool within an existing program.

That changes how the opportunity should be evaluated and positioned. Growers and advisors often think less about the ingredient story and more about the job the product performs in their program. What does it do in the tank, in the canopy, in the soil, or within the overall program? Does it improve coverage, reduce risk, fit a timing window, protect an export market, preserve beneficials, or help manage resistance? These are not just messaging questions. They shape pricing, proof requirements, channel strategy, and the field validation needed before scale.

Distribution realities also belong inside the assessment, not as an afterthought. A market can look attractive on paper and still be difficult to enter if the channel structure does not support adoption. In specialty crops, influence pathways often determine adoption. Retailer preferences, PCA influence, independent consultants, distributor economics, private-label strategies, manufacturer field teams, and branch-level confidence can determine whether a product becomes a meaningful line item or sits quietly in inventory.

A decision-ready assessment should therefore go beyond acres, acre-applications, and estimated dollars. It should show how the market buys, who influences the decision, what switching requires, what proof is needed, and what must be true for the product to earn and keep its place in the program. For protected agriculture, it should also show low, base, and high cases, identify the assumptions that move the result, and clearly explain how the estimate was built.

That is the difference between a market-size estimate and a market-entry tool.

The output should be summarized in one consolidated view: crop, system, region, acres, acre-applications, spend layer, relevant category share, addressable opportunity, evidence quality, key assumptions, and validation priorities. Without that view, a company may have analysis, but it does not yet have a usable decision tool.

The purpose of market sizing is not to eliminate uncertainty. That is not realistic in specialty crops, especially in categories where the data is incomplete. The purpose is to make uncertainty manageable. That requires a clear baseline, a spend stack, a current-market anchor, a modeled-potential case, a sensitivity range, evidence tags, and a short validation plan focused on the assumptions that matter most.

That kind of work gives leadership something actionable. It helps investors judge the quality of the opportunity, commercial teams choose the right starting market, product teams identify the proof required, and channel partners engage around specifics rather than general interest.

In a market where many companies still rely on inflated numbers, incomplete data, or vague adoption assumptions, a defensible market assessment becomes a competitive advantage.

The unseen can be sized. But it has to be sized with discipline.